

Applicants: William C. Olson, et al.  
Serial No.: 09/594,983  
Filed : June 15, 2000  
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions and listings of the claims in the application.

Claims 1-97 (Cancelled).

--98. (currently amended) A monoclonal antibody or a fragment thereof comprising complementarity determining regions (CDRs), wherein at least one of said CDRs bind to an epitope of chemokine receptor 5 (CCR5) and said epitope comprises amino acid residues in (a) an N-terminus of CCR5, (b) one of three extracellular loop regions of CCR5, or (c) a combination thereof, and wherein the antibody or fragment thereof binds to the same epitope as ~~[[is]]~~ antibody PA8 (ATCC Accession No. HB-12605), antibody PA9 (ATCC Accession No. HB-12606), antibody PA10 (ATCC Accession No. HB-12607), antibody PA11 (ATCC Accession No. HB-12608), antibody PA12 (ATCC Accession No. HB-12609) or antibody PA14 (ATCC Accession No. HB-12610).--

--99. (currently amended) A hybridoma producing a monoclonal antibody comprising complementarity determining regions (CDRs), wherein said CDRs bind to an epitope of chemokine receptor 5 (CCR5) and said epitope comprises amino acid residues in (a) an N-terminus of CCR5, (b) one of three extracellular loop regions of CCR5, or (c) a combination thereof, and wherein the antibody or fragment thereof binds to the same epitope as ~~[[is]]~~ antibody PA8 (ATCC Accession No. HB-12605), antibody PA9 (ATCC Accession No. HB-12606), antibody PA10 (ATCC Accession No. HB-12607), antibody PA11 (ATCC Accession No. HB-12608), antibody PA12 (ATCC Accession No. HB-12609) or antibody PA14 (ATCC Accession No. HB-12610).--

Applicants: William C. Olson, et al.  
Serial No.: 09/594,983  
Filed : June 15, 2000  
Page 3

--100. (previously presented) A monoclonal antibody or a fragment thereof, wherein the antibody or fragment thereof binds the same epitope as antibody PA14 (ATCC Accession No. HB-12610).--

--101. (currently amended) A monoclonal antibody or a fragment thereof comprising one or more complementarity determining regions (CDRs) wherein said CDRs are derived from a hybridoma having ATCC Accession No. HB-12610 (PA14).--

--102. (previously presented) The monoclonal antibody or fragment thereof according to any one of claims 98, 100 and 101, wherein the antibody or fragment thereof is humanized.--

--103. (previously presented) The monoclonal antibody according to claim 102, wherein the antibody comprises a framework from a human immunoglobulin molecule.--

--104. (previously presented) The monoclonal antibody according to claim 103, wherein the human immunoglobulin molecule is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.--

Claims 105-116 (Cancelled).

--117. (New) The monoclonal antibody or fragment thereof according to claim 100, wherein the antibody is a humanized antibody.--

--118. (New) The monoclonal antibody or fragment thereof according to claim 101, wherein the antibody is a humanized antibody.--

Applicants: William C. Olson, et al.  
Serial No.: 09/594,983  
Filed : June 15, 2000  
Page 4

--119. (New) The monoclonal antibody or fragment thereof according to claim 117, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.--

--120. (New) The monoclonal antibody or fragment thereof according to claim 117, wherein the antibody comprises a framework from a human IgG4 immunoglobulin molecule.--

--121. (New) The monoclonal antibody or fragment thereof according to claim 118, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.--

--122. (New) The monoclonal antibody or fragment thereof according to claim 118, wherein the antibody comprises a framework from a human IgG4 immunoglobulin molecule.--

--123. (New) The monoclonal antibody or fragment thereof according to claim 100, wherein the antibody is a chimeric antibody.--

--124. (New) The monoclonal antibody or fragment thereof according to claim 101, wherein the antibody is a chimeric antibody.--

--125. (New) The monoclonal antibody or fragment thereof according to claim 123, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.--

--126. (New) The monoclonal antibody or fragment thereof according to claim 123, wherein the antibody comprises a framework from a human IgG4 immunoglobulin molecule.--

--127. (New) The monoclonal antibody or fragment thereof

Applicants: William C. Olson, et al.  
Serial No.: 09/594,983  
Filed : June 15, 2000  
Page 5

according to claim 124, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.--

--128. (New) The monoclonal antibody or fragment thereof according to claim 124, wherein the antibody comprises a framework from a human IgG4 immunoglobulin molecule. --

--129. (New) The monoclonal antibody or fragment thereof according to claim 100, wherein the antibody fragment is a monovalent fragment of an antibody.--

--130. (New) The monoclonal antibody or fragment thereof according to claim 101, wherein the antibody fragment is a monovalent fragment of an antibody.--

--131. (New) The monovalent antibody or fragment thereof according to claim 129, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.--

--132. (New) The monovalent antibody or fragment thereof according to claim 129, wherein the antibody comprises a framework from a human IgG4 immunoglobulin molecule.--

--133. (New) The monovalent antibody or fragment thereof according to claim 130, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.--

--134. (New) The monovalent antibody or fragment thereof according to claim 130, wherein the antibody comprises a framework from a human IgG4 immunoglobulin molecule.--